EORTC 90101 CREATE assesses the antitumour activity and safety of crizotinib across predefined tumour types in patients whose tumours are possibly harbouring specific alterations in ALK and/or MET. (BELG J MED ONCOL 2012;6:129–131)
EORTC 90101 CREATE assesses the antitumour activity and safety of crizotinib across predefined tumour types in patients whose tumours are possibly harbouring specific alterations in ALK and/or MET. (BELG J MED ONCOL 2012;6:129–131)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
